AAAAAA
Results: 1-25/32
Authors:
Eglen, RM
Choppin, A
Watson, N
Citation: Rm. Eglen et al., Therapeutic, opportunities from muscarinic receptor research, TRENDS PHAR, 22(8), 2001, pp. 409-414
Authors:
Novakovic, SD
Eglen, RM
Hunter, JC
Citation: Sd. Novakovic et al., Regulation of Na+ channel distribution in the nervous system, TRENDS NEUR, 24(8), 2001, pp. 473-478
Authors:
Eglen, RM
Citation: Rm. Eglen, Muscarinic receptors and gastrointestinal tract smooth muscle function, LIFE SCI, 68(22-23), 2001, pp. 2573-2578
Authors:
Choppin, A
Eglen, RM
Citation: A. Choppin et Rm. Eglen, Pharmacological characterization of muscarinic receptors in mouse isolatedurinary bladder smooth muscle, BR J PHARM, 133(7), 2001, pp. 1035-1040
Authors:
Meloy, TD
Daniels, DV
Hegde, SS
Eglen, RM
Ford, APDW
Citation: Td. Meloy et al., Functional characterization of rat submaxillary gland muscarinic receptorsusing microphysiometry, BR J PHARM, 132(7), 2001, pp. 1606-1614
Authors:
Choppin, A
Eglen, RM
Citation: A. Choppin et Rm. Eglen, Pharmacological characterization of muscarinic receptors in dog isolated ciliary and urinary bladder smooth muscle, BR J PHARM, 132(4), 2001, pp. 835-842
Authors:
Eglen, RM
Watson, N
Citation: Rm. Eglen et N. Watson, Functional roles of postjunctional muscarinic M-2 receptors in airway smooth muscle, PROG INFLAM, 2001, pp. 87-106
Authors:
Tzoumaka, E
Tischler, AC
Sangameswaran, L
Eglen, RM
Hunter, JC
Novakovic, SD
Citation: E. Tzoumaka et al., Differential distribution of the tetrodotoxin-sensitive rPN4/NaCh6/Scn8a sodium channel in the nervous system, J NEUROSC R, 60(1), 2000, pp. 37-44
Authors:
Claeysen, S
Sebben, M
Becamel, C
Eglen, RM
Clark, RD
Bockaert, J
Dumuis, A
Citation: S. Claeysen et al., Pharmacological properties of 5-hydroxytryptamine(4) receptor antagonists on constitutively active wild-type and mutated receptors, MOLEC PHARM, 58(1), 2000, pp. 136-144
Authors:
Parker, CA
Hudson, AL
Nutt, DJ
Dillon, MP
Eglen, RM
Crosby, J
Citation: Ca. Parker et al., Isolation of RP-HPLC pure clonidine-displacing substance from NG108-15 cells, EUR J PHARM, 387(1), 2000, pp. 27-30
Authors:
Eglen, RM
Nahorski, SR
Citation: Rm. Eglen et Sr. Nahorski, The muscarinic M-5 receptor: a silent or emerging subtype?, BR J PHARM, 130(1), 2000, pp. 13-21
Authors:
Martin, RS
Luong, LA
Welsh, NJ
Eglen, RM
Martin, GR
MacLennan, SJ
Citation: Rs. Martin et al., Effects of cannabinoid receptor agonists on neuronally-evoked contractionsof urinary bladder tissues isolated from rat, mouse, pig, dog, monkey and human, BR J PHARM, 129(8), 2000, pp. 1707-1715
Authors:
MacLennan, SJ
Reynen, PH
Martin, RS
Eglen, RM
Martin, GR
Citation: Sj. Maclennan et al., Characterization of human recombinant alpha(2A)-adrenoceptors expressed inChinese hamster lung cells using extracellular acidification rate changes, BR J PHARM, 129(7), 2000, pp. 1333-1338
Authors:
Reynen, PH
Martin, GR
Eglen, RM
MacLennan, SJ
Citation: Ph. Reynen et al., Characterization of human recombinant alpha(2A)-adrenoceptors expressed inChinese hamster lung cells using intracellular Ca2+ changes: evidence for cross-talk between recombinant alpha(2A)- and native alpha(1)-adrenoceptors, BR J PHARM, 129(7), 2000, pp. 1339-1346
Authors:
Eglen, RM
Hunter, JC
Dray, A
Citation: Rm. Eglen et al., Ions in the fire: recent ion-channel research and approaches to pain therapy, TRENDS PHAR, 20(8), 1999, pp. 337-342
Authors:
Kilpartick, GJ
Dautzenberg, FM
Martin, GR
Eglen, RM
Citation: Gj. Kilpartick et al., 7TM receptors: the splicing on the cake, TRENDS PHAR, 20(7), 1999, pp. 294-301
Authors:
Eglen, RM
Choppin, A
Dillon, MP
Hegde, S
Citation: Rm. Eglen et al., Muscarinic receptor ligands and their therapeutic potential, CURR OP C B, 3(4), 1999, pp. 426-432
Authors:
Eglen, RM
Citation: Rm. Eglen, High throughput screening: Myths and future realities, J BIOMOL SC, 4(4), 1999, pp. 179-181
Authors:
Verity, AN
Wyatt, TL
Lee, W
Hajos, B
Baecker, PA
Eglen, RM
Johnson, RM
Citation: An. Verity et al., Differential regulation of glial cell line-derived neurotrophic factor (GDNF) expression in human neuroblastoma and glioblastoma cell lines, J NEUROSC R, 55(2), 1999, pp. 187-197
Authors:
Novakovic, SD
Kassotakis, LC
Oglesby, IB
Smith, JAM
Eglen, RM
Ford, APDW
Hunter, JC
Citation: Sd. Novakovic et al., Immunocytochemical localization of P-2X3 purinoceptors in sensory neurons in naive rats and following neuropathic injury, PAIN, 80(1-2), 1999, pp. 273-282
Authors:
Baecker, PA
Lee, WH
Verity, AN
Eglen, RM
Johnson, RM
Citation: Pa. Baecker et al., Characterization of a promoter for the human glial cell line-derived neurotrophic factor gene, MOL BRAIN R, 69(2), 1999, pp. 209-222
Authors:
Porreca, F
Lai, J
Bian, D
Wegert, S
Ossipov, MH
Eglen, RM
Kassotakis, L
Novakovic, S
Rabert, DK
Sangameswaran, L
Hunter, JC
Citation: F. Porreca et al., A comparison of the potential role of the tetrodotoxin-insensitive sodium channels, PN3/SNS and NaN/SNS2, in rat models of chronic pain (vol 96, pg 7640, 1999), P NAS US, 96(18), 1999, pp. 10548-10548
Authors:
Porreca, F
Lai, J
Bian, D
Wegert, S
Ossipov, MH
Eglen, RM
Kassotakis, L
Novakovic, S
Rabert, DK
Sangameswaran, L
Hunter, JC
Citation: F. Porreca et al., A comparison of the potential role,of the tetrodotoxin-insensitive sodium channels, PN3/SNS and NaN/SNS2, in rat models of chronic pain, P NAS US, 96(14), 1999, pp. 7640-7644
Authors:
Hegde, SS
Eglen, RM
Citation: Ss. Hegde et Rm. Eglen, Muscarinic receptor subtypes modulating smooth muscle contractility in theurinary bladder, LIFE SCI, 64(6-7), 1999, pp. 419-428
Authors:
Jett, MF
Ramesha, CS
Brown, CD
Chiu, S
Emmett, C
Voronin, T
Sun, T
O'Yang, C
Hunter, JC
Eglen, RM
Johnson, RN
Citation: Mf. Jett et al., Characterization of the analgesic and anti-inflammatory activities of ketorolac and its enantiomers in the rat, J PHARM EXP, 288(3), 1999, pp. 1288-1297